Cannabinoid receptor 1
Also known as: CNR, CNR1
Function
G protein-coupled receptor for endogenous cannabinoids (eCBs), including N-arachidonoylethanolamide (also called anandamide or AEA) and 2-arachidonoylglycerol (2-AG), as well as phytocannabinoids, such as delta(9)-tetrahydrocannabinol (THC). Mediates many cannabinoid-induced effects, acting, among others, on food intake, memory loss, gastrointestinal motility, catalepsy, ambulatory activity, anxiety, chronic pain. Signaling typically involves reduction in cyclic AMP. In the hypothalamus, may have a dual effect on mitochondrial respiration depending upon the agonist dose and possibly upon the cell type. Increases respiration at low doses, while decreases respiration at high doses. At high doses, CNR1 signal transduction involves G protein alpha-i protein activation and subsequent inhibition of mitochondrial soluble adenylate cyclase, decrease in cyclic AMP concentration, inhibition of protein kinase A (PKA)-dependent phosphorylation of specific subunits of the mitochondrial electron transport system, including NDUFS2. In the hypothalamus, inhibits leptin-induced reactive oxygen species (ROS) formation and mediates cannabinoid-induced increase in SREBF1 and FASN gene expression. In response to cannabinoids, drives the release of orexigenic beta-endorphin, but not that of melanocyte-stimulating hormone alpha/alpha-MSH, from hypothalamic POMC neurons, hence promoting food intake. In the hippocampus, regulates cellular respiration and energy production in response to cannabinoids. Involved in cannabinoid-dependent depolarization-induced suppression of inhibition (DSI), a process in which depolarization of CA1 postsynaptic pyramidal neurons mobilizes eCBs, which retrogradely activate presynaptic CB1 receptors, transiently decreasing GABAergic inhibitory neurotransmission. Also reduces excitatory synaptic transmission (By similarity). In superior cervical ganglions and cerebral vascular smooth muscle cells, inhibits voltage-gated Ca(2+) channels in a constitutive, as well as agonist-dependent manner. In cerebral vascular smooth muscle cells, cannabinoid-induced inhibition of voltage-gated Ca(2+) channels leads to vasodilation and decreased vascular tone (By similarity). Induces leptin production in adipocytes and reduces LRP2-mediated leptin clearance in the kidney, hence participating in hyperleptinemia. In adipose tissue, CNR1 signaling leads to increased expression of SREBF1, ACACA and FASN genes (By similarity). In the liver, activation by endocannabinoids leads to increased de novo lipogenesis and reduced fatty acid catabolism, associated with increased expression of SREBF1/SREBP-1, GCK, ACACA, ACACB and FASN genes. May also affect de novo cholesterol synthesis and HDL-cholesteryl ether uptake. Peripherally modulates energy metabolism (By similarity). In high carbohydrate diet-induced obesity, may decrease the expression of mitochondrial dihydrolipoyl dehydrogenase/DLD in striated muscles, as well as that of selected glucose/ pyruvate metabolic enzymes, hence affecting energy expenditure through mitochondrial metabolism (By similarity). In response to cannabinoid anandamide, elicits a pro-inflammatory response in macrophages, which involves NLRP3 inflammasome activation and IL1B and IL18 secretion (By similarity). In macrophages infiltrating pancreatic islets, this process may participate in the progression of type-2 diabetes and associated loss of pancreatic beta-cells.
Classification
- Family (Pfam)
- PF00001 7tm_1
- InterPro
- Canbinoid_rcpt_1, Cnbnoid_rcpt, GPCR_Rhodpsn, GPCR_Rhodpsn_7TM
- Functional cluster
- Ribosomal Proteins & RNA-Processing Enzymes
Experimental structures · PDB · 32
- 1LVQ NMR
- 1LVR NMR
- 2B0Y NMR
- 2KOE NMR
- 2MZ2 NMR
- 2MZ3 NMR
- 2MZA NMR
- 5TGZ X-ray 2.80A
- 5U09 X-ray 2.60A
- 5XR8 X-ray 2.95A
- 5XRA X-ray 2.80A
- 6KPG EM 3.00A
- … and 20 more
A predicted model is available from AlphaFold.
Gene Ontology · 17
- GO:0005737 cytoplasm
- GO:0098982 GABA-ergic synapse
- GO:0098978 glutamatergic synapse
- GO:0030426 growth cone
- GO:0045121 membrane raft
- GO:0005741 mitochondrial outer membrane
- GO:0005886 plasma membrane
- GO:0042734 presynaptic membrane
- GO:0004949 cannabinoid receptor activity
- GO:0004930 G protein-coupled receptor activity
- GO:0042802 identical protein binding
- GO:0007189 adenylate cyclase-activating G protein-coupled receptor signaling pathway
- GO:0007188 adenylate cyclase-modulating G protein-coupled receptor signaling pathway
- GO:0038171 cannabinoid signaling pathway
- GO:0007187 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger
- GO:0099509 regulation of presynaptic cytosolic calcium ion concentration
- GO:0098921 retrograde trans-synaptic signaling by endocannabinoid
Disease associations
- inherited obesity MONDO:0019182
Drugs targeting this protein · 12
- RIMONABANT antagonist
- SURINABANT antagonist
- CANNABIDIOL negative allosteric modulator
- NONABINE agonist
- TARANABANT inverse agonist
- NABILONE agonist
- SAD448 agonist
- DRINABANT antagonist
- AZD2207 antagonist
- IBIPINABANT antagonist
- DRONABINOL agonist
- OTENABANT antagonist
Related proteins · sequence + function similarity
- Cannabinoid receptor 1 1.00
- Cannabinoid receptor 1 1.00
- Cannabinoid receptor 1 1.00
- Cannabinoid receptor 1 1.00
- Cannabinoid receptor 1 0.99
- Cannabinoid receptor 1 0.98
- Cannabinoid receptor 1 0.98
- Cannabinoid receptor type 1A 0.98
- Cannabinoid receptor 1 0.97
- Cannabinoid receptor type 1B 0.97
- Sphingosine 1-phosphate receptor 1 0.85
- Sphingosine 1-phosphate receptor 1 0.85
Co-cited proteins · studied together in the literature
- Cannabinoid receptor 1 5 shared papers
- Guanine nucleotide-binding protein G(i) subunit alpha-2 1 shared papers
- CB1 cannabinoid receptor-interacting protein 1 1 shared papers
- CB1 cannabinoid receptor-interacting protein 1 1 shared papers
- CB1 cannabinoid receptor-interacting protein 1 1 shared papers
- Neurolysin, mitochondrial 1 shared papers
- Thimet oligopeptidase 1 shared papers
- C-C motif chemokine 2 1 shared papers
- Interleukin-1 beta 1 shared papers
- Interleukin-6 1 shared papers
- Hemoglobin subunit alpha-1/2 1 shared papers
- Angiotensin-converting enzyme 1 shared papers
Literature · 22 cited papers
- Molecular mechanism of allosteric modulation for the cannabinoid receptor CB1. Nat. Chem. Biol. · 2022
- Targeting the endocannabinoid system: a predictive, preventive, and personalized medicine-directed approach to the management of brain pathologies. EPMA J. · 2020
- Regional changes in the type 1 cannabinoid receptor are associated with cognitive dysfunction in Parkinson's disease. Eur. J. Nucl. Med. Mol. Imaging · 2019
- Genetic deletion of CB1 cannabinoid receptors exacerbates the Alzheimer-like symptoms in a transgenic animal model. Biochem. Pharmacol. · 2018
- High-resolution crystal structure of the human CB1 cannabinoid receptor. Nature · 2016
- Crystal structure of the human cannabinoid receptor CB1. Cell · 2016
- Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes. Nat. Med. · 2013
- Effects of palmitoylation of Cys(415) in helix 8 of the CB(1) cannabinoid receptor on membrane localization and signalling. Br. J. Pharmacol. · 2012
- Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease. Neuroscience · 2009
- The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab. · 2008
- Hemopressin is an inverse agonist of CB1 cannabinoid receptors. Proc. Natl. Acad. Sci. U.S.A. · 2007
- CB1 cannabinoid receptor activity is modulated by the cannabinoid receptor interacting protein CRIP 1a. Mol. Pharmacol. · 2007
- … and 10 more in the literature graph